Extract
We thank W-J. Guan and colleagues for their comments on the European Respiratory Society (ERS) guidelines for bronchiectasis [1]. We agree these are an important landmark for the field, and hope that clinicians, health professionals, patients and researchers will use the guidelines to improve the quality of care for bronchiectasis patients and to use the gaps identified to stimulate further research [1, 2].
Abstract
Only evidence-based recommendations were included in the @ERStalk bronchiectasis guidelines http://ow.ly/Vecb30g1gJy
Footnotes
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received October 4, 2017.
- Accepted October 5, 2017.
- Copyright ©ERS 2018
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
Vol 51 Issue 1
Table of Contents
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
